Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I,II Open-Label Dose Escalation Study to Evaluate the Safety and Efficacy of Single Doses of TT-034 for Subjects With Chronic Hepatitis C (CHC) Infection

NCT01899092 is registered in ClinicalTrials.gov with Tacere Therapeutics, Inc. as lead sponsor.

NCT NCT01899092
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01899092 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I,II Open-Label Dose Escalation Study to Evaluate the Safety and Efficacy of Single Doses of TT-034 for Subjects With Chronic Hepatitis C (CHC) Infection
Lead sponsor
Tacere Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
January 31, 2014
Completion date
November 30, 2016
Enrollment
9 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c